Advertisement

Breast Cancer Pathology in the Era of Genomics

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Hematology/Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Antoniou A.
        • Pharoah P.D.
        • Narod S.
        • et al.
        Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
        Am J Hum Genet. 2003; 72: 1117-1130
        • Robson M.
        • Im S.A.
        • Senkus E.
        • et al.
        Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
        N Engl J Med. 2017; 377: 523-533
        • Robson M.E.
        • Tung N.
        • Conte P.
        • et al.
        OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
        Ann Oncol. 2019; 30: 558-566
        • Litton J.K.
        • Rugo H.S.
        • Ettl J.
        • et al.
        Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
        N Engl J Med. 2018; 379: 753-763
        • Litton J.K.
        • Hurvitz S.A.
        • Mina L.A.
        • et al.
        Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
        Ann Oncol. 2020; 31: 1526-1535
        • Tutt A.N.J.
        • Garber J.E.
        • Kaufman B.
        • et al.
        Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
        N Engl J Med. 2021; 384: 2394-2405
        • Mandelker D.
        • Zhang L.
        • Kemel Y.
        • et al.
        Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
        Jama. 2017; 318: 825-835
        • Stadler Z.K.
        • Maio A.
        • Chakravarty D.
        • et al.
        Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.
        J Clin Oncol. 2021; 39: 2698-2709
        • Hornick J.L.
        Replacing Molecular Genetic Testing With Immunohistochemistry Using Antibodies That Recognize the Protein Products of Gene Rearrangements: "Next-generation" Immunohistochemistry.
        Am J Surg Pathol. 2021; 45: 584-586
        • Shin S.J.
        • Rosen P.P.
        Solid variant of mammary adenoid cystic carcinoma with basaloid features: a study of nine cases.
        Am J Surg Pathol. 2002; 26: 413-420
        • D'Alfonso T.M.
        • Mosquera J.M.
        • MacDonald T.Y.
        • et al.
        MYB-NFIB gene fusion in adenoid cystic carcinoma of the breast with special focus paid to the solid variant with basaloid features.
        Hum Pathol. 2014; 45: 2270-2280
        • Slodkowska E.
        • Xu B.
        • Kos Z.
        • et al.
        Predictors of Outcome in Mammary Adenoid Cystic Carcinoma: A Multi-Institutional Study.
        Am J Surg Pathol. 2020; 44: 214-223
        • Massé J.
        • Truntzer C.
        • Boidot R.
        • et al.
        Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations.
        Mod Pathol. 2020; 33: 1041-1055
        • Schwartz C.J.
        • Brogi E.
        • Marra A.
        • et al.
        The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features.
        Mod Pathol. 2022; 35: 193-201
        • Persson M.
        • Andrén Y.
        • Mark J.
        • et al.
        Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.
        Proc Natl Acad Sci U S A. 2009; 106: 18740-18744
        • Kim J.
        • Geyer F.C.
        • Martelotto L.G.
        • et al.
        MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene.
        J Pathol. 2018; 244: 143-150
        • West R.B.
        • Kong C.
        • Clarke N.
        • et al.
        MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation.
        Am J Surg Pathol. 2011; 35: 92-99
        • Brill 2nd, L.B.
        • Kanner W.A.
        • Fehr A.
        • et al.
        Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms.
        Mod Pathol. 2011; 24: 1169-1176
        • Tognon C.
        • Knezevich S.R.
        • Huntsman D.
        • et al.
        Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.
        Cancer Cell. 2002; 2: 367-376
        • Hechtman J.F.
        • Benayed R.
        • Hyman D.M.
        • et al.
        Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
        Am J Surg Pathol. 2017; 41: 1547-1551
        • Harrison B.T.
        • Fowler E.
        • Krings G.
        • et al.
        Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the Breast.
        Am J Surg Pathol. 2019; 43: 1693-1700
        • Hoda R.S.
        • Brogi E.
        • Pareja F.
        • et al.
        Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential.
        Histopathology. 2019; 75: 213-224
        • Shukla N.
        • Roberts S.S.
        • Baki M.O.
        • et al.
        Successful Targeted Therapy of Refractory Pediatric ETV6-NTRK3 Fusion-Positive Secretory Breast Carcinoma.
        JCO Precis Oncol. 2017; 2017
        • Chiang S.
        • Weigelt B.
        • Wen H.C.
        • et al.
        IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity.
        Cancer Res. 2016; 76: 7118-7129
        • Pareja F.
        • da Silva E.M.
        • Frosina D.
        • et al.
        Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity.
        Mod Pathol. 2020; 33: 1056-1064
        • Geyer F.C.
        • Li A.
        • Papanastasiou A.D.
        • et al.
        Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.
        Nat Commun. 2018; 9: 1816
        • Watanabe S.
        • Otani T.
        • Iwasa T.
        • et al.
        A Case of Metastatic Malignant Breast Adenomyoepithelioma With a Codon-61 Mutation of HRAS.
        Clin Breast Cancer. 2019; 19: e589-e592
        • Pareja F.
        • Toss M.S.
        • Geyer F.C.
        • et al.
        Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas.
        Histopathology. 2020; 76: 865-874
        • Paik S.
        • Shak S.
        • Tang G.
        • et al.
        A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
        N Engl J Med. 2004; 351: 2817-2826
        • van de Vijver M.J.
        • He Y.D.
        • van't Veer L.J.
        • et al.
        A gene-expression signature as a predictor of survival in breast cancer.
        N Engl J Med. 2002; 347: 1999-2009
        • Parker J.S.
        • Mullins M.
        • Cheang M.C.
        • et al.
        Supervised risk predictor of breast cancer based on intrinsic subtypes.
        J Clin Oncol. 2009; 27: 1160-1167
        • Filipits M.
        • Rudas M.
        • Jakesz R.
        • et al.
        A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
        Clin Cancer Res. 2011; 17: 6012-6020
        • Ma X.J.
        • Salunga R.
        • Dahiya S.
        • et al.
        A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer.
        Clin Cancer Res. 2008; 14: 2601-2608
      1. Gradishar WJ, Moran MS, Abraham J et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 20, 2022, 691-722; Accessed July 2022.

        • Harris L.N.
        • Ismaila N.
        • McShane L.M.
        • et al.
        Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
        J Clin Oncol. 2016; 34: 1134-1150
        • Krop I.
        • Ismaila N.
        • Andre F.
        • et al.
        Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
        J Clin Oncol. 2017; 35: 2838-2847
        • Andre F.
        • Ismaila N.
        • Henry N.L.
        • et al.
        Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.
        J Clin Oncol. 2019; 37: 1956-1964
        • Andre F.
        • Ismaila N.
        • Allison K.H.
        • et al.
        Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
        J Clin Oncol. 2022; 40: 1816-1837
        • Coates A.S.
        • Winer E.P.
        • Goldhirsch A.
        • et al.
        Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
        Ann Oncol. 2015; 26: 1533-1546
        • Burstein H.J.
        • Curigliano G.
        • Loibl S.
        • et al.
        Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.
        Ann Oncol. 2019; 30: 1541-1557
        • Burstein H.J.
        • Curigliano G.
        • Thürlimann B.
        • et al.
        Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.
        Ann Oncol. 2021; 32: 1216-1235
        • Amin M.B.
        • Greene F.L.
        • Edge S.B.
        • et al.
        The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.
        CA Cancer J Clin. 2017; 67: 93-99
        • Sparano J.A.
        • Gray R.J.
        • Makower D.F.
        • et al.
        Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
        N Engl J Med. 2015; 373: 2005-2014
        • Sparano J.A.
        • Gray R.J.
        • Makower D.F.
        • et al.
        Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
        N Engl J Med. 2018; 379: 111-121
        • Kalinsky K.
        • Barlow W.E.
        • Gralow J.R.
        • et al.
        21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
        N Engl J Med. 2021; 385: 2336-2347
        • Mamounas E.P.
        • Tang G.
        • Fisher B.
        • et al.
        Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
        J Clin Oncol. 2010; 28: 1677-1683
        • Mamounas E.P.
        • Liu Q.
        • Paik S.
        • et al.
        21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
        J Natl Cancer Inst. 2017; 109
        • Turashvili G.
        • Chou J.F.
        • Brogi E.
        • et al.
        21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.
        Breast Cancer Res Treat. 2017; 166: 69-76
        • van 't Veer L.J.
        • Dai H.
        • van de Vijver M.J.
        • et al.
        Gene expression profiling predicts clinical outcome of breast cancer.
        Nature. 2002; 415: 530-536
        • Cardoso F.
        • van't Veer L.J.
        • Bogaerts J.
        • et al.
        70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
        N Engl J Med. 2016; 375: 717-729
        • Sparano J.A.
        • Gray R.J.
        • Ravdin P.M.
        • et al.
        Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
        N Engl J Med. 2019; 380: 2395-2405
        • Sparano J.A.
        • Crager M.R.
        • Tang G.
        • et al.
        Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer.
        J Clin Oncol. 2021; 39: 557-564
        • Turashvili G.
        • Brogi E.
        • Morrow M.
        • et al.
        The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
        Breast Cancer Res Treat. 2017; 165: 65-76
        • Tadros A.B.
        • Wen H.Y.
        • Morrow M.
        Breast Cancers of Special Histologic Subtypes Are Biologically Diverse.
        Ann Surg Oncol. 2018; 25: 3158-3164
        • Allison K.H.
        • Hammond M.E.H.
        • Dowsett M.
        • et al.
        Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
        J Clin Oncol. 2020; 38: 1346-1366
        • Wolff A.C.
        • Hammond M.E.H.
        • Allison K.H.
        • et al.
        Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
        J Clin Oncol. 2018; 36: 2105-2122
        • O'Connor S.M.
        • Beriwal S.
        • Dabbs D.J.
        • et al.
        Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors.
        Appl Immunohistochem Mol Morphol. 2010; 18: 268-272
        • Kraus J.A.
        • Dabbs D.J.
        • Beriwal S.
        • et al.
        Semi-quantitative immunohistochemical assay versus oncotype DX(®) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study.
        Mod Pathol. 2012; 25: 869-876
        • Park M.M.
        • Ebel J.J.
        • Zhao W.
        • et al.
        ER and PR immunohistochemistry and HER2 FISH versus oncotype DX: implications for breast cancer treatment.
        Breast J. 2014; 20: 37-45
        • Neely C.
        • You S.
        • Mendoza P.M.
        • et al.
        Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
        Breast J. 2018; 24: 889-893
        • Dabbs D.J.
        • Klein M.E.
        • Mohsin S.K.
        • et al.
        High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.
        J Clin Oncol. 2011; 29: 4279-4285
        • Yerushalmi R.
        • Woods R.
        • Ravdin P.M.
        • et al.
        Ki67 in breast cancer: prognostic and predictive potential.
        Lancet Oncol. 2010; 11: 174-183
        • Cheang M.C.
        • Chia S.K.
        • Voduc D.
        • et al.
        Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
        J Natl Cancer Inst. 2009; 101: 736-750
        • Goldhirsch A.
        • Wood W.C.
        • Coates A.S.
        • et al.
        Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
        Ann Oncol. 2011; 22: 1736-1747
        • Goldhirsch A.
        • Winer E.P.
        • Coates A.S.
        • et al.
        Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.
        Ann Oncol. 2013; 24: 2206-2223
        • Nielsen T.O.
        • Leung S.C.Y.
        • Rimm D.L.
        • et al.
        Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.
        J Natl Cancer Inst. 2021; 113: 808-819
        • Johnston S.R.D.
        • Harbeck N.
        • Hegg R.
        • et al.
        Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
        J Clin Oncol. 2020; 38: 3987-3998
        • Harbeck N.
        • Rastogi P.
        • Martin M.
        • et al.
        Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
        Ann Oncol. 2021; 32: 1571-1581
        • Denkert C.
        • Loibl S.
        • Noske A.
        • et al.
        Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.
        J Clin Oncol. 2010; 28: 105-113
        • Denkert C.
        • von Minckwitz G.
        • Darb-Esfahani S.
        • et al.
        Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
        Lancet Oncol. 2018; 19: 40-50
        • Loi S.
        • Sirtaine N.
        • Piette F.
        • et al.
        Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
        J Clin Oncol. 2013; 31: 860-867
        • Loi S.
        • Drubay D.
        • Adams S.
        • et al.
        Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
        J Clin Oncol. 2019; 37: 559-569
        • Salgado R.
        • Denkert C.
        • Demaria S.
        • et al.
        The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
        Ann Oncol. 2015; 26: 259-271
        • Loi S.
        • Michiels S.
        • Adams S.
        • et al.
        The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.
        Ann Oncol. 2021; 32: 1236-1244
        • Chakravarty D.
        • Gao J.
        • Phillips S.M.
        • et al.
        OncoKB: A Precision Oncology Knowledge Base.
        JCO Precis Oncol. 2017; 2017
        • Han G.
        • Schell M.J.
        • Reisenbichler E.S.
        • et al.
        Determination of the number of observers needed to evaluate a subjective test and its application in two PD-L1 studies.
        Stat Med. 2022; 41: 1361-1375
        • Reisenbichler E.S.
        • Han G.
        • Bellizzi A.
        • et al.
        Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.
        Mod Pathol. 2020; 33: 1746-1752
        • Schmid P.
        • Cortes J.
        • Pusztai L.
        • et al.
        Pembrolizumab for Early Triple-Negative Breast Cancer.
        N Engl J Med. 2020; 382: 810-821
        • Sajjadi E.
        • Venetis K.
        • Piciotti R.
        • et al.
        Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization.
        Cancer Cell Int. 2021; 21: 266
        • Schiavon G.
        • Hrebien S.
        • Garcia-Murillas I.
        • et al.
        Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.
        Sci Transl Med. 2015; 7: 313ra182
        • Clatot F.
        • Perdrix A.
        • Beaussire L.
        • et al.
        Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer.
        Breast Cancer Res. 2020; 22: 56
        • Dahlgren M.
        • George A.M.
        • Brueffer C.
        • et al.
        Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer.
        JNCI Cancer Spectr. 2021; 5
        • Burstein H.J.
        • Somerfield M.R.
        • Barton D.L.
        • et al.
        Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
        J Clin Oncol. 2021; 39: 3959-3977
        • Modi S.
        • Park H.
        • Murthy R.K.
        • et al.
        Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
        J Clin Oncol. 2020; 38: 1887-1896
        • Modi S.
        • Jacot W.
        • Yamashita T.
        • et al.
        Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
        N Engl J Med. 2022; 387: 9-20
        • Hyman D.M.
        • Piha-Paul S.A.
        • Won H.
        • et al.
        HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
        Nature. 2018; 554: 189-194
        • André F.
        • Ciruelos E.
        • Rubovszky G.
        • et al.
        Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
        N Engl J Med. 2019; 380: 1929-1940
        • Martínez-Sáez O.
        • Chic N.
        • Pascual T.
        • et al.
        Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
        Breast Cancer Res. 2020; 22: 45
        • Pérez-Fidalgo J.A.
        • Criscitiello C.
        • Carrasco E.
        • et al.
        A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer.
        Future Oncol. 2022; 18: 2339-2349
        • Turner N.C.
        • Kingston B.
        • Kilburn L.S.
        • et al.
        Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
        Lancet Oncol. 2020; 21: 1296-1308
        • Rose Brannon A.
        • Jayakumaran G.
        • Diosdado M.
        • et al.
        Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS.
        Nat Commun. 2021; 12: 3770
        • Dawson S.J.
        • Tsui D.W.
        • Murtaza M.
        • et al.
        Analysis of circulating tumor DNA to monitor metastatic breast cancer.
        N Engl J Med. 2013; 368: 1199-1209
        • Fribbens C.
        • Garcia Murillas I.
        • Beaney M.
        • et al.
        Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
        Ann Oncol. 2018; 29: 145-153
        • O'Leary B.
        • Hrebien S.
        • Morden J.P.
        • et al.
        Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
        Nat Commun. 2018; 9: 896
        • O'Leary B.
        • Cutts R.J.
        • Liu Y.
        • et al.
        The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.
        Cancer Discov. 2018; 8: 1390-1403
        • Paoletti C.
        • Schiavon G.
        • Dolce E.M.
        • et al.
        Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.
        Clin Cancer Res. 2018; 24: 5860-5872
        • Hrebien S.
        • Citi V.
        • Garcia-Murillas I.
        • et al.
        Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.
        Ann Oncol. 2019; 30: 945-952
        • O'Leary B.
        • Cutts R.J.
        • Huang X.
        • et al.
        Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
        J Natl Cancer Inst. 2021; 113: 309-317
        • Kingston B.
        • Cutts R.J.
        • Bye H.
        • et al.
        Genomic profile of advanced breast cancer in circulating tumour DNA.
        Nat Commun. 2021; 12: 2423
        • Bardia A.
        • Su F.
        • Solovieff N.
        • et al.
        Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib.
        JCO Precis Oncol. 2021; 5
        • Tolaney S.M.
        • Toi M.
        • Neven P.
        • et al.
        Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
        Clin Cancer Res. 2022; 28: 1500-1506
        • Radovich M.
        • Jiang G.
        • Hancock B.A.
        • et al.
        Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
        JAMA Oncol. 2020; 6: 1410-1415
        • Magbanua M.J.M.
        • Swigart L.B.
        • Wu H.T.
        • et al.
        Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
        Ann Oncol. 2021; 32: 229-239
        • Garcia-Murillas I.
        • Chopra N.
        • Comino-Méndez I.
        • et al.
        Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.
        JAMA Oncol. 2019; 5: 1473-1478
        • Penson A.
        • Camacho N.
        • Zheng Y.
        • et al.
        Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care.
        JAMA Oncol. 2020; 6: 84-91